https://m2.mtmt.hu/ hun 2026-09-20 16:19 JournalArticle 32848262 VALIDATED true 0 false 2026-08-28T11:18:06.685+0000 2026-01-28T15:24:25.018+0000 2022-05-29T14:20:36.856+0000 true 10034246 Kupai József /api/author/10034246 Author Kupai József (Szerves kémia) true 10034246 2026-06-18T10:34:22.786+0000 2025-11-11T14:56:43.332+0000 true 10072271 Andódy Katalin /api/admin/10072271 Admin Andódy Katalin (BME admin4) true Admin 10063514 /api/admin/10063514 Mikola Katalin (MTMT 3, admin) Mikola Katalin true 10063514 true 2025-12-16T21:23:24.713+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Pósa, Szonja Polett true true /api/journal/11300 REVIEWED BIOORGANIC & MEDICINAL CHEMISTRY 0968-0896 1464-3391 true false 11300 false 11300 true 0968-0896 1464-3391 Journal FOREIGN 67 116855 116855 7 2022 Since the first application of natural quinine as an anti-malarial drug, cinchona alkaloids and their derivatives have been exhaustively studied for their biological activity. In our work, we tested 13 cinchona alkaloid organocatalysts, synthesised from quinine. These derivatives were screened against MES-SA and Dx5 uterine sarcoma cell lines for in vitro anticancer activity and to investigate their potential to overcome P-glycoprotein (P-gp) mediated multidrug resistance (MDR). Decorating quinine with hydrogen-bond donor units, such as thiourea and (thio)squaramide, resulted in decreased half-maximal growth inhibition values on both cell lines (1.3–21 µM) compared to quinine and other cinchona alcohols (47–111 µM). Further cytotoxicity studies conducted in the presence of the P-gp inhibitor tariquidar indicated that several analogues, especially cinchona amines and squaramides, but not thiosquaramide, were expelled from MDR cells by P-gp. Similarly to the established P-gp inhibitor quinine, 6 cinchona analogues were shown to inhibit calcein-AM efflux. Interestingly, quinine and didehydroquinine exhibited a marginally increased toxicity against the multidrug resistant Dx5 cells. Collateral sensitivity of the MDR cell line was more pronounced when the cinchona thiosquaramide was complexed with Cu(II) acetate. Based on the results, cinchona derivatives are good anticancer candidates for further drug development. Funding 2015139 /api/funding/2015139 (2019-1.3.1-KK-2019-00007) Támogató: NKFIH false true Funding 2016000 /api/funding/2016000 (ÚNKP-20-5-BME-322) false true Funding 2016001 /api/funding/2016001 (János Bolyai Research Scholarship) false true Funding 2016002 /api/funding/2016002 (FK138037) false true Funding 2016003 /api/funding/2016003 (Kiválósági Együttműködési Program) Támogató: MTA false true Funding 2051832 /api/funding/2051832 (0983-20 405) Támogató: MTA false true true true INTERNATIONAL 2022 true true true false true false GOLD 2026-08-28 true https://doi.org/10.1016/j.bmc.2022.116855 14 0 14 12 2 14 14 13 12 14 14 12 12 12 2 0 14 12 14 12 0 11 11 Folyóiratcikk Journal Article 24 14 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 1 1 1 1 2023 0 4 4 4 4 2024 0 4 3 4 3 2025 0 3 2 3 2 2026 0 2 2 2 2 Q2 false false false false 2022-06-09T06:26:13.664+0000 Enzimológiai Intézet (TTK); Farmakognóziai Intézet (SE / GYTK); Szerves Kémia és Technológia Tanszék (BME / VBK) 8 25 3 9 0 true 10063514 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 101855146 /api/authorship/101855146 Pósa, Szonja Polett [Pósa, Szonja Polett (Onkológia), szerző] 1 0.11111111 true false false Author 10096768 /api/author/10096768 Pósa Szonja Polett (Onkológia) Pósa Szonja Polett true true Pósa Szonja Polett true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 101855147 /api/authorship/101855147 Dargó, Gyula [Dargó, Gyula (szerves kémia), szerző] Szerves Kémia és Technológia Tanszék (BME / VBK) 2 0.111 false false false Author 10062822 /api/author/10062822 Dargó Gyula (szerves kémia) Dargó Gyula true 10062822 true Dargó Gyula true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 101855148 /api/authorship/101855148 Nagy, Sándor 3 0.11111111 false false false Nagy Sándor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 101855149 /api/authorship/101855149 Kisszékelyi, Péter [Kisszékelyi, Péter (szerves kémia), szerző] Szerves Kémia és Technológia Tanszék (BME / VBK) 4 0.11111111 false false false Author 10055883 /api/author/10055883 Kisszékelyi Péter (szerves kémia) Kisszékelyi Péter true 10055883 true Kisszékelyi Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 101855150 /api/authorship/101855150 Garádi, Zsófia [Garádi, Zsófia (NMR spektroszkópia), szerző] Farmakognóziai Intézet (SE / GYTK) 5 0.111 false false false Author 10070153 /api/author/10070153 Garádi Zsófia (NMR spektroszkópia) Garádi Zsófia true true Garádi Zsófia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 101855151 /api/authorship/101855151 Hámori, Lilla [Hámori, Lilla (Tumorsejtbiológia), szerző] Enzimológiai Intézet (TTK) 6 0.111 false false false Author 10053930 /api/author/10053930 Hámori Lilla (Tumorsejtbiológia) Hámori Lilla true 10053930 true Hámori Lilla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 101855152 /api/authorship/101855152 Szakács, Gergely [Szakács, Gergely (Biokémia, membrán...), szerző] Enzimológiai Intézet (TTK) 7 0.111 false false false Author 10001932 /api/author/10001932 Szakács Gergely (Biokémia, membránbiológia) Szakács Gergely true 10001932 true Szakács Gergely true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 101855153 /api/authorship/101855153 Kupai, József ✉ [Kupai, József (Szerves kémia), szerző] Szerves Kémia és Technológia Tanszék (BME / VBK) 8 0.111 false false true Author 10034246 /api/author/10034246 Kupai József (Szerves kémia) Kupai József true 10034246 true Kupai József true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 101855154 /api/authorship/101855154 Tóth, Szilárd ✉ [Tóth, Szilárd (Molekuláris biológia), szerző] 9 0.111 false true true Author 10032964 /api/author/10032964 Tóth Szilárd (Molekuláris biológia) Tóth Szilárd true 10032964 true Tóth Szilárd true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 21054666 /api/publicationidentifier/21054666 DOI: 10.1016/j.bmc.2022.116855 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.bmc.2022.116855 https://doi.org/10.1016/j.bmc.2022.116855 false true PublicationIdentifier 21111417 /api/publicationidentifier/21111417 SE Repozitórium: 9170 SwordSource 84 /api/publicationsource/84 SE Repozitórium PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true SE Repozitórium SE Repozitórium https://repo.lib.semmelweis.hu/handle/123456789/@@@ true true 84 true GREEN true IDENTICAL 9170 https://repo.lib.semmelweis.hu/handle/123456789/9170 false true PublicationIdentifier 21265038 /api/publicationidentifier/21265038 WoS: 000811873300011 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000811873300011 https://www.webofscience.com/wos/woscc/full-record/000811873300011 false true PublicationIdentifier 21265039 /api/publicationidentifier/21265039 Scopus: 85131572042 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85131572042 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85131572042 false true PublicationIdentifier 21103499 /api/publicationidentifier/21103499 PubMed: 35640378 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 35640378 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35640378&dopt=Abstract true true PublicationIdentifier 31583298 /api/publicationidentifier/31583298 Egyéb URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131572042&doi=10.1016%2Fj.bmc.2022.116855&partnerID=40&md5=48879940c9194627284e192e39e590da PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131572042&doi=10.1016%2Fj.bmc.2022.116855&partnerID=40&md5=48879940c9194627284e192e39e590da https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131572042&doi=10.1016%2Fj.bmc.2022.116855&partnerID=40&md5=48879940c9194627284e192e39e590da false true Classification 12197 /api/classification/12197 Gyógyszerészet, farmakogenomika, gyógyszerkutatás és tervezés, gyógyszeres kezelés true true SjrRating 11284476 /api/sjrrating/11284476 sjr:Q2 (2022) Scopus - Clinical Biochemistry BIOORGANIC & MEDICINAL CHEMISTRY 0968-0896 1464-3391 60 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1308 /api/classificationexternal/1308 Scopus - Clinical Biochemistry true 1308 true Q2 DIRECT true true Reference 31089312 /api/reference/31089312 1. Marcelli 2010: Hiemstra Cinchona Alkaloids in Asymmetric Organocatalysis., Synthesis, 2010, p. 1229, DOI: 10.1055/s-0029-1218699 1 10.1055/s-0029-1218699 false true Reference 31089313 /api/reference/31089313 2. Ridley 2002: Medical need, scientific opportunity and the drive for antimalarial drugs., Nature, 415, p. 686, DOI: 10.1038/415686a 2 10.1038/415686a false true Reference 31089314 /api/reference/31089314 3. Achan 2011: D’Alessandro Quinine, an old anti-malarial drug in a modern world: Role in the treatment of malaria., Malar. J., 10, p. 1, DOI: 10.1186/1475-2875-10-144 3 10.1186/1475-2875-10-144 false true Reference 31089315 /api/reference/31089315 4. Sheldon 1995: Lou Koshman Antiarrhythmic activity of quinine in humans., Circulation, 92, p. 2944, DOI: 10.1161/01.CIR.92.10.2944 4 10.1161/01.CIR.92.10.2944 false true Reference 31089316 /api/reference/31089316 5. S. Malakar, L. Sreelatha, T. Dechtawewat, S. Noisakran, P. thai Yenchitsomanus, J.J.H. Chu, T. Limjindaporn Drug repurposing of quinine as antiviral against dengue virus infection. Virus Res. 2018, 255, 171–178. https://doi.org/10.1016/j.virusres.2018.07.018., DOI: 10.1016/j.virusres.2018.07.018 5 10.1016/j.virusres.2018.07.018 false true Reference 31089317 /api/reference/31089317 6. Baroni 2007: Donnarumma Antiviral effects of quinine sulfate on HSV-1 HaCat cells infected: Analysis of the molecular mechanisms involved., J. Dermatological Sci., 47, p. 253, DOI: 10.1016/j.jdermsci.2007.05.009 6 10.1016/j.jdermsci.2007.05.009 false true Reference 31089318 /api/reference/31089318 7. Wolf 2002: Ruocco Quinine sulfate and bacterial invasion., Ann. Clin. Microbiol. Antimicrob., 1, p. 1, DOI: 10.1186/1476-0711-1-5 7 10.1186/1476-0711-1-5 false true Reference 31089319 /api/reference/31089319 8. Quintana 2016: Triola Squaramides with cytotoxic activity against human gastric carcinoma cells HGC-27: Synthesis and mechanism of action., MedChemComm, 7, p. 550, DOI: 10.1039/C5MD00515A 8 10.1039/C5MD00515A false true Reference 31089320 /api/reference/31089320 9. Kacprzak 2018: Steverding Cytotoxic and trypanocidal activities of cinchona alkaloid derivatives., Chem. Biol. Drug Des., 92, p. 1778, DOI: 10.1111/cbdd.13346 9 10.1111/cbdd.13346 false true Reference 31089321 /api/reference/31089321 10. Pires 2009: Chmielewski Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers., Mol. Pharmacol., 75, p. 92, DOI: 10.1124/mol.108.050492 10 10.1124/mol.108.050492 false true Reference 31089322 /api/reference/31089322 11. Kuriakose 2012: Chmielewski Click chemistry-derived bivalent quinine inhibitors of P-glycoprotein- mediated cellular efflux. Bioorganic Med., Chem. Lett., 22, p. 4410, DOI: 10.1016/j.bmcl.2012.04.125 11 10.1016/j.bmcl.2012.04.125 false true Reference 31089323 /api/reference/31089323 12. Podolski-Renić 2017: Pešić Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel., Metallomics, 9, p. 1132, DOI: 10.1039/C7MT00183E 12 10.1039/C7MT00183E false true Reference 31089324 /api/reference/31089324 13. Baraniak 2011: Celewicz Synthesis of 3′-azido-3′-deoxythymidine (AZT) - Cinchona alkaloid conjugates via click chemistry: Toward novel fluorescent markers and cytostatic agents. Bioorganic Med., Chem. Lett., 21, p. 723, DOI: 10.1016/j.bmcl.2010.11.127 13 10.1016/j.bmcl.2010.11.127 false true Reference 31089325 /api/reference/31089325 14. Boratyński 2018: Wietrzyk Triazole Biheterocycles from Cinchona Alkaloids: Coordination and Antiproliferative Properties., ChemistrySelect, 3, p. 9368, DOI: 10.1002/slct.201801810 14 10.1002/slct.201801810 false true Reference 31089326 /api/reference/31089326 15. Skiera 2015: Huczyński Antiproliferative Activity of Polyether Antibiotic - Cinchona Alkaloid Conjugates Obtained via Click Chemistry., Chem. Biol. Drug Des., 86, p. 911, DOI: 10.1111/cbdd.12523 15 10.1111/cbdd.12523 false true Reference 31089327 /api/reference/31089327 16. Akhtar 2020: Manna Quinine-Based Semisynthetic Ion Transporters with Potential Antiproliferative Activities., ACS Appl. Mater. Interfaces, 12, p. 25521, DOI: 10.1021/acsami.0c01259 16 10.1021/acsami.0c01259 false true Reference 31089328 /api/reference/31089328 17. Szakács 2014: Di Pietro Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance., Chem. Rev., 114, p. 5753, DOI: 10.1021/cr4006236 17 10.1021/cr4006236 false true Reference 31089329 /api/reference/31089329 18. Palmeira 2012: Pinto Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds., Curr. Med. Chem., 19, p. 1946, DOI: 10.2174/092986712800167392 18 10.2174/092986712800167392 false true Reference 31089330 /api/reference/31089330 19. Xu 2015: Qiu Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomes., Int. J. Nanomedicine, 10, p. 4225 19 false true Reference 31089331 /api/reference/31089331 20. Solary 2003: Harousseau Quinine as a multidrug resistance inhibitor: A phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia., Blood, 102, p. 1202, DOI: 10.1182/blood-2002-11-3419 20 10.1182/blood-2002-11-3419 false true Reference 31089332 /api/reference/31089332 21. Younes 1997: Cabanillas Paclitaxel activity for the treatment of non-Hodgkin’s lymphoma: Final report of a phase II trial., Br. J. Haematol., 96, p. 328, DOI: 10.1046/j.1365-2141.1997.d01-2012.x 21 10.1046/j.1365-2141.1997.d01-2012.x false true Reference 31089333 /api/reference/31089333 22. Vezmar 2000: Georges Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs., Biochem. Pharmacol., 59, p. 1245, DOI: 10.1016/S0006-2952(00)00270-7 22 10.1016/S0006-2952(00)00270-7 false true Reference 31089334 /api/reference/31089334 23. Chauffert 1990: Martin Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice., Br. J. Cancer, 62, p. 395, DOI: 10.1038/bjc.1990.305 23 10.1038/bjc.1990.305 false true Reference 31089335 /api/reference/31089335 24. Taylor 1997: Salmon Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer., Breast Cancer Res. Treat., 42, p. 7, DOI: 10.1023/A:1005716214718 24 10.1023/A:1005716214718 false true Reference 31089336 /api/reference/31089336 25. Bennis 1995: Robert Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line., Int. J. Cancer, 62, p. 283, DOI: 10.1002/ijc.2910620309 25 10.1002/ijc.2910620309 false true Reference 31089337 /api/reference/31089337 26. Lee 2011: Kim Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells., Environ. Toxicol., 26, p. 424, DOI: 10.1002/tox.20568 26 10.1002/tox.20568 false true Reference 31089338 /api/reference/31089338 27. Solary 1991: Guy Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM., Cancer, 68, p. 1714, DOI: 10.1002/1097-0142(19911015)68:8&lt;1714::AID-CNCR2820680811&gt;3.0.CO;2-2 27 10.1002/1097-0142(19911015)68:8&lt;1714::AID-CNCR2820680811&gt;3.0.CO;2-2 false true Reference 31089339 /api/reference/31089339 28. Solary 1992: Guy Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia., J. Clin. Oncol., 10, p. 1730, DOI: 10.1200/JCO.1992.10.11.1730 28 10.1200/JCO.1992.10.11.1730 false true Reference 31089340 /api/reference/31089340 29. Miller 1998: Salmon A phase I/II trial of paclitaxel for non-Hodgkin’s lymphoma followed by paclitaxel plus quinine in drug-resistant disease., Anticancer Drugs, 9, p. 135, DOI: 10.1097/00001813-199802000-00004 29 10.1097/00001813-199802000-00004 false true Reference 31089341 /api/reference/31089341 30. Szakács 2004: Gottesman Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells., Cancer Cell, 6, p. 129, DOI: 10.1016/j.ccr.2004.06.026 30 10.1016/j.ccr.2004.06.026 false true Reference 31089342 /api/reference/31089342 31. Connon 2006: Organocatalysis Mediated by (Thio)urea Derivatives., Chem. Eur. J., 12, p. 5418, DOI: 10.1002/chem.200501076 31 10.1002/chem.200501076 false true Reference 31089343 /api/reference/31089343 32. Storer 2011: Jones Squaramides: physical properties, synthesis and applications., Chem. Soc. Rev., 40, p. 2330, DOI: 10.1039/c0cs00200c 32 10.1039/c0cs00200c false true Reference 31089344 /api/reference/31089344 33. Rombola 2017: Rawal Development of Chiral, Bifunctional Thiosquaramides: Enantioselective Michael Additions of Barbituric Acids to Nitroalkenes., J. Am. Chem. Soc., 139, p. 5297, DOI: 10.1021/jacs.7b01115 33 10.1021/jacs.7b01115 false true Reference 31089345 /api/reference/31089345 34. S. Nagy, P. Kisszékelyi, J. Kupai Synthesis and Application of Thiosquaramides and Their Derivatives: A Review. Period. Polytech. Chem. Eng. 2018, 62, 467–475–467–475. https://doi.org/10.3311/PPCH.12851., DOI: 10.3311/PPch.12851 34 10.3311/PPch.12851 false true Reference 31089346 /api/reference/31089346 35. Nagy 2019: Kupai Comparison of cinchona catalysts containing ethyl or vinyl or ethynyl group at their quinuclidine ring., Materials, 12, p. 3034, DOI: 10.3390/ma12183034 35 10.3390/ma12183034 false true Reference 31089347 /api/reference/31089347 36. G. Kardos, T. Soós Tether-Free Immobilized Bifunctional Squaramide Organocatalysts for Batch and Flow Reactions. Eur. J. Org. Chem. 2013, 2013, 4490–4494. https://doi.org/10.1002/EJOC.201300626., DOI: 10.1002/ejoc.201300626 36 10.1002/ejoc.201300626 false true Reference 31089348 /api/reference/31089348 37. Nagy 2019: Kupai New enantiopure binaphthyl-cinchona thiosquaramides: synthesis and application for enantioselective organocatalysis., New J. Chem., 43, p. 5948, DOI: 10.1039/C8NJ06451B 37 10.1039/C8NJ06451B false true Reference 31089349 /api/reference/31089349 38. M. Rombola, V.H. Rawal Dicyclopentyl Dithiosquarate as an Intermediate for the Synthesis of Thiosquaramides. Org. Lett. 2018, 20, 514–517. https://doi.org/10.1021/acs.orglett.7b03549., DOI: 10.1021/acs.orglett.7b03549 38 10.1021/acs.orglett.7b03549 false true Reference 31089350 /api/reference/31089350 39. Genne 1992: Chauffert Cinchonine, a Potent Efflux Inhibitor to Circumvent Anthracycline Resistance In Vivo., Cancer Res., 52, p. 2797 39 false true Reference 31089351 /api/reference/31089351 40. Windt 2019: Szakács Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen., Arch. Toxicol., 93, p. 953, DOI: 10.1007/s00204-019-02417-6 40 10.1007/s00204-019-02417-6 false true Reference 31089352 /api/reference/31089352 41. A.K. Ghose, V.N. Viswanadhan, J.J. Wendoloski A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1999, 1, 55–68. https://doi.org/10.1021/cc9800071., DOI: 10.1021/cc9800071 41 10.1021/cc9800071 false true Reference 31089353 /api/reference/31089353 42. Füredi 2017: Szakács Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein–Induced Toxicity., Mol. Cancer Ther., 16, p. 45, DOI: 10.1158/1535-7163.MCT-16-0333-T 42 10.1158/1535-7163.MCT-16-0333-T false true Reference 31089354 /api/reference/31089354 43. (accessed September 2021)https://clinicaltrials.gov/ct2/show/NCT00726414. 43 false true Reference 31089355 /api/reference/31089355 44. Frigo 1977: Salerno Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations., Br. J. Clin. Pharmacol., 4, p. 449, DOI: 10.1111/j.1365-2125.1977.tb00760.x 44 10.1111/j.1365-2125.1977.tb00760.x false true Reference 31089356 /api/reference/31089356 45. Wishart 2016: Leonard Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial., J. Clin. Oncol., 12, p. 1771, DOI: 10.1200/JCO.1994.12.9.1771 45 10.1200/JCO.1994.12.9.1771 false true Reference 31089357 /api/reference/31089357 46. Ross 2004: Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract. Res., Clin. Haematol., 17, p. 641 46 false true Reference 31089358 /api/reference/31089358 47. Solary 1996: Harousseau Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study., Blood, 88, p. 1198, DOI: 10.1182/blood.V88.4.1198.bloodjournal8841198 47 10.1182/blood.V88.4.1198.bloodjournal8841198 false true Reference 31089359 /api/reference/31089359 48. C.H. Keith, F.R. Maxfield, M.L. Shelanski Intracellular free calcium levels are reduced in mitotic Pt K2 epithelial cells. Proc. Natl. Acad. Sci. 1985, 82, 800–804. https://doi.org/10.1073/PNAS.82.3.800., DOI: 10.1073/pnas.82.3.800 48 10.1073/pnas.82.3.800 false true Reference 31089360 /api/reference/31089360 49. J.M. Tsangaris, T.A. Kabanos Circular dichroism of the complexes of quinine with copper(II), nickel(II), cobalt(II), chromium(III) and palladium(II) chlorides. Monatshefte Für Chemie Chem. Mon. 1982, 113, 1393–1398. https://doi.org/10.1007/BF00808938., DOI: 10.1007/BF00808938 49 10.1007/BF00808938 false true Reference 31089361 /api/reference/31089361 50. J.M. Tsangaris, G.T.H. Baxevanidis Complexes of Quinine with Cu(II), Ni(II), Co(II) and Cr(III) Chlorides. Zeitschrift Fur Naturforsch. - Sect. B J. Chem. Sci. 1974, 29, 532–537. https://doi.org/10.1515/znb-1974-7-815., DOI: 10.1515/znb-1974-7-815 50 10.1515/znb-1974-7-815 false true Reference 31089362 /api/reference/31089362 51. N.A. Rey, K.C. Dos Santos, M.Â.B.C. Menezes, A.S. Mangrich, E.C. Pereira-Maia Two different modes for copper(II) ion coordination to quinine-type ligands. J. Braz. Chem. Soc. 2006, 17, 497–504. https://doi.org/10.1590/S0103-50532006000300010., DOI: 10.1590/S0103-50532006000300010 51 10.1590/S0103-50532006000300010 false true Reference 31089363 /api/reference/31089363 52. U. Jungwirth, C.R. Kowol, B.K. Keppler, C.G. Hartinger, W. Berger, P. Heffeter Anticancer activity of metal complexes: Involvement of redox processes. Antioxidants Redox Signal. 2011, 15, 1085–1127. https://doi.org/10.1089/ars.2010.3663., DOI: 10.1089/ars.2010.3663 52 10.1089/ars.2010.3663 false true Reference 31089364 /api/reference/31089364 53. A.P. King, J.J. Wilson Endoplasmic reticulum stress: An arising target for metal-based anticancer agents. Chem. Soc. Rev. 2020, 49, 8113–8136. https://doi.org/10.1039/d0cs00259c., DOI: 10.1039/D0CS00259C 53 10.1039/D0CS00259C false true Reference 31089365 /api/reference/31089365 54. J.M. Myers, W.E. Antholine, J. Zielonka, C.R. Myers The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress. Toxicol. Lett. 2011, 201, 130–136. https://doi.org/10.1016/j.toxlet.2010.12.017., DOI: 10.1016/j.toxlet.2010.12.017 54 10.1016/j.toxlet.2010.12.017 false true Reference 31089366 /api/reference/31089366 55. Hager 2020: Heffeter High Copper Complex Stability and Slow Reduction Kinetics as Key Parameters for Improved Activity, Paraptosis Induction, and Impact on Drug-Resistant Cells of Anticancer Thiosemicarbazones. Antioxidants Redox., Signal., 33, p. 395 55 false true Reference 31089367 /api/reference/31089367 56. R.A. Finch, M.C. Liu, A.H. Cory, J.G. Cory, A.C. Sartorelli Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): An inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzym. Regul. 1999, 39, 3–12. https://doi.org/10.1016/S0065-2571(98)00017-X., DOI: 10.1016/S0065-2571(98)00017-X 56 10.1016/S0065-2571(98)00017-X false true Reference 31089368 /api/reference/31089368 57. (accesed September 2021). https://clinicaltrials.gov/ct2/show/NCT02688101. 57 false true Reference 31089369 /api/reference/31089369 58. L. Homolya, M. Holló, M. Müller, E. Mechetner, B. Sarkadi A new method for quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br. J. Cancer 1996 737 1996, 73, 849–855. https://doi.org/10.1038/bjc.1996.151., DOI: 10.1038/bjc.1996.151 58 10.1038/bjc.1996.151 false true /api/publication/32848262 Pósa Szonja Polett et al. Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines. (2022) BIOORGANIC & MEDICINAL CHEMISTRY 0968-0896 1464-3391 67<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10096768"><a href="/gui2/?type=authors&mode=browse&sel=10096768" target="_blank">Pósa Szonja Polett (<span class="authorship-author-name">Pósa Szonja Polett</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10062822"><a href="/gui2/?type=authors&mode=browse&sel=10062822" target="_blank">Dargó Gyula (<span class="authorship-author-name">Dargó Gyula</span> <span class="authorAux-mtmt"> szerves kémia</span>) </a> </span> <span class="author-affil"><span title="Budapesti Műszaki és Gazdaságtudományi Egyetem">BME</span>/<span title="Vegyészmérnöki és Biomérnöki Kar">VBK</span>/Szerves Kémia és Technológia Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Nagy Sándor </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10055883"><a href="/gui2/?type=authors&mode=browse&sel=10055883" target="_blank">Kisszékelyi Péter (<span class="authorship-author-name">Kisszékelyi Péter</span> <span class="authorAux-mtmt"> szerves kémia</span>) </a> </span> <span class="author-affil"><span title="Budapesti Műszaki és Gazdaságtudományi Egyetem">BME</span>/<span title="Vegyészmérnöki és Biomérnöki Kar">VBK</span>/Szerves Kémia és Technológia Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10070153"><a href="/gui2/?type=authors&mode=browse&sel=10070153" target="_blank">Garádi Zsófia (<span class="authorship-author-name">Garádi Zsófia</span> <span class="authorAux-mtmt"> NMR spektroszkópia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Farmakognóziai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10053930"><a href="/gui2/?type=authors&mode=browse&sel=10053930" target="_blank">Hámori Lilla (<span class="authorship-author-name">Hámori Lilla</span> <span class="authorAux-mtmt"> Tumorsejtbiológia</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/Enzimológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10001932"><a href="/gui2/?type=authors&mode=browse&sel=10001932" target="_blank">Szakács Gergely (<span class="authorship-author-name">Szakács Gergely</span> <span class="authorAux-mtmt"> Biokémia, membránbiológia</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/Enzimológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10034246"><a href="/gui2/?type=authors&mode=browse&sel=10034246" target="_blank">Kupai József ✉ (<span class="authorship-author-name">Kupai József</span> <span class="authorAux-mtmt"> Szerves kémia</span>) </a> </span> <span class="author-affil"><span title="Budapesti Műszaki és Gazdaságtudományi Egyetem">BME</span>/<span title="Vegyészmérnöki és Biomérnöki Kar">VBK</span>/Szerves Kémia és Technológia Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10032964"><a href="/gui2/?type=authors&mode=browse&sel=10032964" target="_blank">Tóth Szilárd ✉ (<span class="authorship-author-name">Tóth Szilárd</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32848262" target="_blank">Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines</a></div> <div> <span class="journal-title">BIOORGANIC & MEDICINAL CHEMISTRY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0968-0896">0968-0896</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1464-3391">1464-3391</a>)</span>: <span class="journal-volume">67</span> <span class="page"> Paper 116855. 7 p. </span> <span class="year">(2022)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.bmc.2022.116855" target="_blank" href="https://doi.org/10.1016/j.bmc.2022.116855"> DOI </a> </span> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:blue" title="9170" target="_blank" href="https://repo.lib.semmelweis.hu/handle/123456789/9170"> SE Repozitórium </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000811873300011" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000811873300011"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85131572042" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85131572042"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="35640378" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35640378&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_NONE" title=" Nincs "> <a style="color:blue" title="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131572042&doi=10.1016%2Fj.bmc.2022.116855&partnerID=40&md5=48879940c9194627284e192e39e590da" target="_blank" href="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131572042&doi=10.1016%2Fj.bmc.2022.116855&partnerID=40&md5=48879940c9194627284e192e39e590da"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Clinical Biochemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Drug Discovery&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Organic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmaceutical Science&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biochemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q3</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Molecular Biology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q3</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Molecular Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q3</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 14</span> | Független: 12 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 13 | Scopus jelölt:&nbsp;12 | WoS/Scopus jelölt:&nbsp;14 | DOI jelölt:&nbsp;14 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32848262&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 11 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32848262</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (2019-1.3.1-KK-2019-00007) Támogató: NKFIH, (ÚNKP-20-5-BME-322), (János Bolyai Research Scholarship), (FK138037), (Kiválósági Együttműködési Program) Támogató: MTA, (0983-20 405) Támogató: MTA </div> <div class="lastModified">Utolsó módosítás: 2026.01.28. 16:24 Balázs András (MTMT Központ, admin) </div> <div class="lockedBy">Központi kezelésű 2025.12.16. 22:23 Mikola Katalin (MTMT 3, admin) </div> </div></div>